搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Mouse Fibroblast growth factor 15(FGF15) ELISA kit

Mouse Fibroblast growth factor 15(FGF15) ELISA kit

  • 中文名稱：
    小鼠成纖維細(xì)胞生長因子15(FGF15)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-EL522052MO
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    小鼠成纖維細(xì)胞生長因子15(FGF15)酶聯(lián)免疫試劑盒（CSB-EL522052MO）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿、細(xì)胞裂解物樣本中的FGF15含量。FGF15，全稱成纖維細(xì)胞生長因子15，是一種腸道激素，參與調(diào)節(jié)膽汁酸、葡萄糖和脂質(zhì)代謝等，維持全身穩(wěn)態(tài)。研究顯示，F(xiàn)GF15通過血液作用于多個(gè)組織器官，調(diào)控腸肝軸和系統(tǒng)代謝，其失調(diào)可能促進(jìn)多種疾病。研究機(jī)制方面，F(xiàn)GF15在肝臟中抑制膽汁酸生物合成，并通過表觀遺傳機(jī)制調(diào)控脂肪生成。試劑盒檢測范圍為15.6 pg/ml- 1000 pg/ml，靈敏度為3.9 pg/ml。適用于體外研究FGF15在代謝性疾病模型、腸道損傷修復(fù)、肝臟再生調(diào)控以及神經(jīng)系統(tǒng)發(fā)育等實(shí)驗(yàn)中的表達(dá)變化，可為探索FGF15信號通路機(jī)制及靶向干預(yù)研究提供可靠工具本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    FGF-15 ELISA Kit; Fgf15 ELISA Kit; FGF15_MOUSE ELISA Kit; FGF19 ELISA Kit; Fibroblast growth factor 15 ELISA Kit
  • 縮寫：
    FGF15
  • Uniprot No.：
  • 種屬：
    Mus musculus (Mouse)
  • 樣本類型：
    serum, plasma, tissue homogenates, cell lysates
  • 檢測范圍：
    15.6 pg/ml - 1000 pg/ml
  • 靈敏度：
    3.9 pg/ml
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Signal Transduction
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度：

    To assess the linearity of the assay, samples were spiked with high concentrations of mouse FGF15 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

    　

    Sample

    Serum(n=4)

    1:1

    Average %

    89

    Range %

    84-95

    1:2

    Average %

    90

    Range %

    85-98

    1:4

    Average %

    95

    Range %

    90-100

    1:8

    Average %

    92

    Range %

    87-97

  • 回收率：

    The recovery of mouse FGF15 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    98

    93-103

    EDTA plasma (n=4)

    96

    91-104

  • 標(biāo)準(zhǔn)曲線：

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    pg/ml

    OD1

    OD2

    Average

    Corrected

    1000

    2.754

    2.622

    2.688

    2.580

    500

    2.215

    2.185

    2.200

    2.092

    250

    1.534

    1.496

    1.515

    1.407

    125

    0.699

    0.647

    0.673

    0.565

    62.5

    0.366

    0.358

    0.362

    0.254

    31.2

    0.265

    0.249

    0.257

    0.149

    15.6

    0.187

    0.179

    0.183

    0.075

    0

    0.112

    0.103

    0.108

    　

  • 本試劑盒所含材料：
      • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human FGF15 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
      • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
      • One vial Biotin-labeled FGF15 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
      • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
      • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
      • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
      • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
      • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
      • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
      • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
      • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
      • An instruction manual

    顯示更多

    收起更多

  • 本試劑盒不含材料：
      • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
      • An incubator can provide stable incubation conditions up to 37°C±5°C.
      • Centrifuge
      • Vortex
      • Squirt bottle, manifold dispenser, or automated microplate washer
      • Absorbent paper for blotting the microtiter plate
      • 50-300ul multi-channel micropipette
      • Pipette tips
      • Single-channel micropipette with different ranges
      • 100ml and 500ml graduated cylinders
      • Deionized or distilled water
      • Timer
      • Test tubes for dilution

    顯示更多

    收起更多

  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價(jià)

平均分:
4.0分 - 1 個(gè)評價(jià)

樣品類型：血清

樣品信息：小鼠

稀釋比：沒有稀釋

產(chǎn)品評價(jià)： 我使用CSB-E1522052MO，檢測小鼠血清樣本中的 FGF-15 濃度。在檢測過程中，通過酶標(biāo)儀在 450nm 波長下測定吸光度（O.D. 值0.0185-3.0335），顏色的深淺和樣品中的目標(biāo)呈正相關(guān)，根據(jù)標(biāo)準(zhǔn)曲線可以計(jì)算出樣品的濃度。在實(shí)際測樣過程中，嚴(yán)格按照試劑盒說明書進(jìn)行操作，能得到較為可靠的結(jié)果。操作流程相對簡便。說明書詳細(xì)地列出了實(shí)驗(yàn)步驟及注意事項(xiàng)。即使是初次使用的實(shí)驗(yàn)者也能較快上手。該試劑盒的穩(wěn)定性較好，。

By 張老師

相關(guān)問答

■ 常見問題解答
Q:

We are now interested in your following product.
Please let us know delivery time and the sulfuric acid content of [stop solution] .

A:
Thanks for your interest!The delievery time of the mentioned kit is supposed to be 2-3 business days and the sulfuric acid content of [stop solution] is 4N.

靶點(diǎn)詳情

  • 最新研究進(jìn)展：
    FGF15是一種膽固醇代謝調(diào)節(jié)蛋白，在研究中已經(jīng)發(fā)現(xiàn)與糖尿病、肥胖、非酒精性脂肪性肝病等代謝疾病有關(guān)。最新的研究表明，F(xiàn)GF15還參與了神經(jīng)遞質(zhì)釋放、嗜睡調(diào)節(jié)以及生物鐘調(diào)節(jié)等生理過程。研究發(fā)現(xiàn)，F(xiàn)GF15誘導(dǎo)的生物鐘調(diào)節(jié)與肝臟鐘基因相互作用，從而影響動物行為和代謝狀態(tài)，這為肥胖、糖尿病和心血管疾病等代謝性疾病的治療提供了新的治療策略。
  • 功能：
    Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression.
  • 基因功能參考文獻(xiàn)：
    1. Taken together, these results suggested that FGF19, through the anti-oxidative defense system, attenuated the development of diabetic cardiomyopathy and restored cardiac function. PMID: 29778534
    2. ileal FGF15/19 to hepatic FGFR4 axis is activated and promotes liver regeneration (LR) after partial hepatectomy (PH) in mice, supporting the potential of ileal FGF15/19 to hepatic FGFR4 axis-targeted therapy to enhance LR after PH PMID: 29468415
    3. FRS2alpha-mediated pathways are essential for the FGF15/FGF19-FGFR4 signaling axis to control bile acid homeostasis. PMID: 25056539
    4. Together, our results show that SuFu promotes cerebellar radial precursor differentiation to neurons. SuFu function is mediated in part by GLI3R and down-regulation of Fgf15 expression. PMID: 28560839
    5. Results show a reciprocal regulation of adiponectin and FGF19 gene expression in mice. PMID: 27666676
    6. Tumorigenicity was assessed in three mouse models (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient) following continuous exposure to FGF19 or FGF15 via adeno-associated viral-mediated gene delivery. PMID: 28189755
    7. These data identify hypothalamic Fgf15 as a regulator of glucagon secretion. PMID: 27829151
    8. Intestinal sensing of highly elevated levels of conjugated bile acids in blood promotes FGF15 signaling, reducing hepatic bile acid synthesis and modulating bile acid transporters. PMID: 28498614
    9. Fgf15 is the sonic hedgehog downstream signal to control thalamic regionalization, neurogenesis, and neuronal differentiation by regulating the expression and mutual segregation of neurogenic and proneural regulatory genes. PMID: 26311466
    10. human microbiota was able to reduce the levels of tauro-beta-muricholic acid and induce expression of FXR target genes Fgf15 and Shp in ileum after long-term colonization. We show that a human microbiota can change BA composition and induce FXR signaling in colonized mice, but the levels of secondary BAs produced are lower than in mice colonized with a mouse microbiota PMID: 27956475
    11. FGF15 improves lipid homeostasis and reduces bile acid synthesis, but promotes fibrosis during the development of non-alcoholic steatohepatitis PMID: 28673684
    12. This study demonstrates that the FGF19-SHP-LSD1 axis maintains homeostasis by suppressing unnecessary autophagic breakdown of cellular components, including lipids, under nutrient-rich postprandial conditions. PMID: 28446510
    13. The elevation in circulating levels of adiponectin and Fgf15 led to normalized hepatic and serum levels of bile acids, limited hepatic accumulation of toxic bile, attenuated inflammation, and amelioration of liver injury in the ethanol-fed mNT knockout mice. PMID: 27573244
    14. This study reveals SHP as a global transcriptional partner of SREBP-2 in regulation of sterol biosynthetic gene networks and provides a potential mechanism for cholesterol-lowering action of FGF19. PMID: 26634251
    15. we suggest that considerable mechanistic differences exist between humans and mice with regard to the nuclear receptors controlling the VitA-FGF15/19 axis. PMID: 26723851
    16. Ileal Fgf15 expression is a potent inhibitor of bile acid synthesis. PMID: 26040986
    17. Protective effects of farnesoid X receptor on hepatic lipid accumulation are mediated by hepatic FXR and are independent of intestinal FGF15 signaling. PMID: 25156247
    18. In mice with humanized livers human hepatocytes do not recognize FGF-15 produced by mouse intestine, resulting in up-regulation of bile acid synthesis enlargement of the bile acid pool, affecting the hepatostat. PMID: 26028580
    19. Intestinal PPARalpha-UDP- Glucuronyltransferases and downstream FXR-FGF15 signalling play vital roles in control of bile acid homeostasis and the pathological development of colitis. PMID: 25183423
    20. Sstudy shows an important contribution of ileal FGF15 to hepatocarcinogenesis in a clinically relevant mouse model where lack of Fgf15 resulted in reduced tumor burden and attenuated tumor progression. PMID: 25346390
    21. results suggest that FGF15 deficiency severely impairs liver regeneration in mice after PHx. The underlying mechanism is likely the result of disrupted bile acid homeostasis and impaired priming of hepatocyte proliferation. PMID: 24699334
    22. a direct role of intestinal FGF15/19 in the regulation of SI P450 expression and may have profound implications for the prediction of drug exposure in patients with compromised hepatic P450 function PMID: 24184963
    23. findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the brain's capacity to rapidly, potently, and selectively increase insulin-independent glucose disposal PMID: 24084738
    24. Total ileal FGF15 expression was elevated almost 20-fold in Ostalpha(-/-) mice as a result of increased villus epithelial cell number and ileocyte FGF15 protein expression PMID: 22542490
    25. generated a variant of FGF19, FGF19-7, that has altered receptor specificity with a strong bias toward FGFR1c PMID: 22457778
    26. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PMID: 22442730
    27. Mouse Fgf15 and human FGF19 play key roles in enterohepatic signaling, regulation of liver bile acid biosynthesis, gallbladder motility and metabolic homeostasis PMID: 22396169
    28. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice PMID: 21747170
    29. mice lacking FGF15 (FGF19) fail to maintain blood concentrations of glucose and normal postprandial liver glycogen; FGF19 activates a physiologically important, insulin-independent endocrine pathway that regulates hepatic protein and glycogen metabolism PMID: 21436455
    30. Fgf15 is a crucial signaling molecule regulating the postmitotic transition of dorsal neural progenitors and thus the initiation and proper progression of dorsal midbrain neurogenesis in the mouse. PMID: 21172336
    31. the physiological relevance of the contribution of the intestinal FXR-Fgf15 signalling pathway in control of hepatic bile acid synthesis PMID: 20531290
    32. the structure-function relationship of FGF19/FGF21 and the structural basis underpinning the distinct proliferative feature of FGF19 compared with FGF21 PMID: 20660733
    33. activation of FGFR4 is the mechanism whereby FGF19 can increase hepatocyte proliferation and induce hepatocellular carcinoma formation. PMID: 20018895
    34. Fgf15 is expressed in the optic vesicle, a subset of progenitor cells of neural retina, and emerging ganglion and amacrine cells during retinogenesis PMID: 15465490
    35. Fgf15 is directly regulated by Shh signaling through Gli proteins in the developing diencephalon and midbrain PMID: 15614767
    36. in the mouse, loss of FG15 gene function results in high penetrant VSDs and alignment defects of the aorta and pulmonary trunk PMID: 15789410
    37. fibroblast growth factor 15 (FGF15) signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway PMID: 16213224
    38. identified two enhancers: one directed lacZ expression in the hindbrain/spinal cord and the other in the posterior midbrain (pmb), rhombomere1 (r1) and pharyngeal epithelia PMID: 16930954
    39. compare the expression pattern during neural development of chick Fgf19 with mouse Fgf15. PMID: 17654705
    40. These findings suggest that the repressor form of Gli2 preferentially binds to the GliREs to control Fgf15 expression. PMID: 18279667
    41. FGF15 and FGF8 have distinct signaling properties, and opposite effects on neocortical patterning and differentiation PMID: 18625063
    42. The results of this study indicate that both beta-Klotho and FGF-15/19 repress the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. PMID: 18772362
    43. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action PMID: 19237543
    44. Results suggest that FGF19-regulated liver bile acid metabolism could be independent of its glucose-lowering effect, and direct FGFR activation in adipose tissue may play an important role in the regulation of glucose homeostasis. PMID: 19706524

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 蛋白家族：
    Heparin-binding growth factors family
  • 組織特異性：
    Expressed in the developing brain.
  • 數(shù)據(jù)庫鏈接：

    KEGG: mmu:14170

    STRING: 10090.ENSMUSP00000033389

    UniGene: Mm.3904